Datapoint: FDA Postpones Review for Lilly’s Alzheimer’s Drug

The FDA will take longer than expected to make a decision on Eli Lilly & Co.’s donanemab. The Alzheimer’s drug was originally slated for an approval decision as early as this week. According to NBC News, the FDA informed Lilly that it wants more data on the drug’s safety and effectiveness. If approved, the drug would compete with Eisai Co., Ltd. and Biogen Inc.’s Leqembi (Iecanemab-irmb). The controversial therapy holds covered or better status for just 36% of all insured lives.

SOURCE: MMIT Analytics, as of 3/18/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 24

Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today